$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000078516116000136 Filed on July 29, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$920.7M	$764.4M
YoY Change	20.45%	26.47%
Cost Of Revenue	$34.40M	$31.70M
YoY Change	8.52%	14.03%
Gross Profit	$870.9M	$721.8M
YoY Change	20.66%	27.23%
Gross Profit Margin	94.59%	94.43%
Selling, General & Admin	$540.1M	$446.5M
YoY Change	20.96%	36.21%
% of Gross Profit	62.02%	61.86%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$42.90M	$32.70M
YoY Change	31.19%	23.86%
% of Gross Profit	4.93%	4.53%
Operating Expenses	$704.5M	$583.4M
YoY Change	20.76%	32.68%
Operating Profit	$150.2M	$123.4M
YoY Change	21.72%	-3.29%
Interest Expense	$43.40M	-$28.60M
YoY Change	-251.75%	13.49%
% of Operating Profit	28.89%	-23.18%
Other Income/Expense, Net	$700.0K	$3.000M
YoY Change	-76.67%	-89.36%
Pretax Income	$123.7M	$94.00M
YoY Change	31.6%	-28.02%
Income Tax	$42.40M	$32.20M
% Of Pretax Income	34.28%	34.26%
Net Earnings	$62.60M	$42.90M
YoY Change	45.92%	-48.38%
Net Earnings / Revenue	6.8%	5.61%
Basic Earnings Per Share	$0.70	$0.47
Diluted Earnings Per Share	$0.65	$0.45
COMMON SHARES
Basic Shares Outstanding	89.30M shares	89.80M shares
Diluted Shares Outstanding	99.40M shares	101.5M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.30M	$45.50M
YoY Change	54.51%	-30.85%
Cash & Equivalents	$70.30M	$45.50M
Short-Term Investments
Other Short-Term Assets	$168.6M	$126.7M
YoY Change	33.07%	21.94%
Inventory
Prepaid Expenses
Receivables	$420.6M	$351.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$659.5M	$712.4M
YoY Change	-7.43%	22.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.337B	$1.063B
YoY Change	25.79%	8.84%
Goodwill	$1.900B	$1.098B
YoY Change	73.09%	3053.74%
Intangibles	$414.2M	$325.5M
YoY Change	27.25%	215.1%
Long-Term Investments
YoY Change
Other Assets	$206.8M	$191.6M
YoY Change	7.93%	29.46%
Total Long-Term Assets	$3.973B	$2.757B
YoY Change	44.1%	38.16%
TOTAL ASSETS
Total Short-Term Assets	$659.5M	$712.4M
Total Long-Term Assets	$3.973B	$2.757B
Total Assets	$4.633B	$3.470B
YoY Change	33.52%	34.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$67.10M	$60.00M
YoY Change	11.83%	7.72%
Accrued Expenses	$355.5M	$283.2M
YoY Change	25.53%	16.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$36.50M	$21.40M
YoY Change	70.56%
Total Short-Term Liabilities	$459.1M	$364.6M
YoY Change	25.92%	21.82%
LONG-TERM LIABILITIES
Long-Term Debt	$3.050B	$2.104B
YoY Change	44.93%	42.66%
Other Long-Term Liabilities	$154.1M	$137.3M
YoY Change	12.24%	-2.69%
Total Long-Term Liabilities	$154.1M	$137.3M
YoY Change	12.24%	-2.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$459.1M	$364.6M
Total Long-Term Liabilities	$154.1M	$137.3M
Total Liabilities	$3.663B	$2.606B
YoY Change	40.55%	36.06%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$672.7M	$605.9M
YoY Change
Total Liabilities & Shareholders Equity	$4.633B	$3.470B
YoY Change	33.52%	34.66%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	$62.60M	$42.90M
YoY Change	45.92%	-48.38%
Depreciation, Depletion And Amortization	$42.90M	$32.70M
YoY Change	31.19%	23.86%
Cash From Operating Activities	$152.2M	$102.9M
YoY Change	47.91%	-19.61%
INVESTING ACTIVITIES
Capital Expenditures	-$47.50M	-$34.90M
YoY Change	36.1%	-5.42%
Acquisitions
YoY Change
Other Investing Activities	-$18.50M	-$46.10M
YoY Change	-59.87%	1904.35%
Cash From Investing Activities	-$66.00M	-$81.00M
YoY Change	-18.52%	106.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-89.10M	-184.7M
YoY Change	-51.76%	142.71%
NET CHANGE
Cash From Operating Activities	152.2M	102.9M
Cash From Investing Activities	-66.00M	-81.00M
Cash From Financing Activities	-89.10M	-184.7M
Net Change In Cash	-2.900M	-162.8M
YoY Change	-98.22%	-1381.89%
FREE CASH FLOW
Cash From Operating Activities	$152.2M	$102.9M
Capital Expenditures	-$47.50M	-$34.90M
Free Cash Flow	$199.7M	$137.8M
YoY Change	44.92%	-16.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89770417	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	4000000000	USD
	dei	Entity Registrant Name EntityRegistrantName	HEALTHSOUTH CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016Q2	hls	Consolidatedcoverageratiominimum Consolidatedcoverageratiominimum	2
CY2015Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2016Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2015Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-3800000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-7700000	USD
CY2016Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-5800000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-12100000	USD
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.029
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2015Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	0	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	8000000	USD
CY2016Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	0	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	0	USD
CY2015Q2	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	2600000	USD
	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	2600000	USD
CY2016Q2	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	0	USD
	hls	Gross Realized Gains Losses Availableforsale Securities Sale Proceedsand Increase Decreaseon Derivative GrossRealizedGainsLossesAvailableforsaleSecuritiesSaleProceedsandIncreaseDecreaseonDerivative	0	USD
CY2015Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	44200000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	85100000	USD
CY2016Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	62500000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	120400000	USD
CY2015Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	46800000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	91900000	USD
CY2016Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	65100000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	125600000	USD
CY2015Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	42600000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	83200000	USD
CY2016Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	62400000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	120200000	USD
CY2015Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	753500000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1482500000	USD
CY2016Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	905300000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1798600000	USD
CY2016Q2	hls	Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures	6	facilities
CY2016Q2	hls	Number Of Partially Owned Subsidiaries Nonconsolidated NumberOfPartiallyOwnedSubsidiariesNonconsolidated	7	facilities
	hls	Numberof Facilities Consolidated As Variable Interest Entities NumberofFacilitiesConsolidatedAsVariableInterestEntities	10	facilities
CY2015Q2	hls	Occupancy Cost OccupancyCost	12500000	USD
	hls	Occupancy Cost OccupancyCost	24600000	USD
CY2016Q2	hls	Occupancy Cost OccupancyCost	17900000	USD
	hls	Occupancy Cost OccupancyCost	35900000	USD
	hls	Ownership Percentage Of Subsidiary Guarantors OwnershipPercentageOfSubsidiaryGuarantors	1.00
CY2015Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.101
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.100
CY2016Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.100
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.098
CY2015Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.031
CY2016Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.032
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.033
CY2015Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.745
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.747
CY2016Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.747
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.751
CY2015Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.013
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.013
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3900000	USD
CY2016Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.014
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.012
CY2015Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.018
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.016
CY2016Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.014
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.014
CY2015Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.006
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.006
CY2016Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.005
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.005
CY2015Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2016Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2015Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.009
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.009
CY2016Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.007
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.008
CY2015Q2	hls	Percentageof Net Operating Revenues Medicare Advantage PercentageofNetOperatingRevenuesMedicareAdvantage	0.077
	hls	Percentageof Net Operating Revenues Medicare Advantage PercentageofNetOperatingRevenuesMedicareAdvantage	0.080
CY2016Q2	hls	Percentageof Net Operating Revenues Medicare Advantage PercentageofNetOperatingRevenuesMedicareAdvantage	0.081
	hls	Percentageof Net Operating Revenues Medicare Advantage PercentageofNetOperatingRevenuesMedicareAdvantage	0.079
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	11800000	USD
	hls	Premium Paid On Redemption Of Bonds PremiumPaidOnRedemptionOfBonds	3900000	USD
	hls	Premiumreceivedonbondissuance Premiumreceivedonbondissuance	8000000	USD
	hls	Premiumreceivedonbondissuance Premiumreceivedonbondissuance	0	USD
CY2015Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	100000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	2300000	USD
CY2016Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	1700000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	1900000	USD
CY2016Q2	hls	Seniorsecuredleverageratiomaximum Seniorsecuredleverageratiomaximum	1.75
	hls	Stock Issued During Period Value Conversionof Preferred Stock StockIssuedDuringPeriodValueConversionofPreferredStock	93200000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	16600000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	9900000	USD
	hls	Treasury Stock Value Acquired Cost Method Common Stock TreasuryStockValueAcquiredCostMethodCommonStock	24100000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	61600000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	67100000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	410500000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	420600000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14900000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11500000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	83800000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	153800000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	39300000	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	48900000	USD
CY2015Q4	us-gaap	Assets Assets	4606100000	USD
CY2016Q2	us-gaap	Assets Assets	4632600000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	598700000	USD
CY2015Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	3171500000	USD
CY2016Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	3086500000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	659500000	USD
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	43000000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	85800000	USD
CY2016Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	62600000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	120700000	USD
CY2015Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	766900000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1510100000	USD
CY2016Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	921200000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1833000000	USD
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	-800000	USD
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	3000000	USD
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	288200000	USD
CY2016Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	283500000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66700000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45500000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61600000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70300000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-21200000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8700000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-300000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-500000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.21
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.42
CY2016Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.23
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.46
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	43000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	85600000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	62800000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	120900000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	17300000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33800000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	18600000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	37300000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	60300000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	119400000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	81400000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	158200000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	93200000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	615100000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1223600000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	738900000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1471700000	USD
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	8700000	USD
CY2016Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	5000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	55600000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	73200000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	190800000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	115500000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	115500000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27600000	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32700000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	64600000	USD
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42900000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85300000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	38000000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	41700000	USD
CY2015Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1600000	USD
CY2016Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1600000	USD
CY2015Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2016Q2	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2015Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2016Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.94
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.34
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.26
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	15500000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	3700000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	3000000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	4800000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	10000000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	4800000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	8700000	USD
CY2016Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	5000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	10000000	USD
CY2015Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	8900000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	17100000	USD
CY2016Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	10900000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	22100000	USD
CY2015Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-800000	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	700000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-200000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1900000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-100000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-200000	USD
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2015Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2300000	USD
CY2016Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2400000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4800000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62500000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	82100000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1700000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1200000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	62100000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59500000	USD
CY2016Q2	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-200000	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-400000	USD
CY2015Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-18800000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-20000000	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2400000	USD
CY2016Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2000000	USD
CY2016Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2400000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4800000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32100000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66700000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34400000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66300000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	1890100000	USD
CY2016Q2	us-gaap	Goodwill Goodwill	1899700000	USD
CY2015Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	764400000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1505000000	USD
CY2016Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	920700000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1830500000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	44500000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	87300000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	62700000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	120800000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	17300000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	33800000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	18600000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	37300000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	94000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	183600000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	123700000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	240200000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	61800000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	121100000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	81300000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	158100000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.49
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.96
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.70
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.34
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.47
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.91
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.65
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.26
CY2015Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1600000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1900000	USD
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-100000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-23600000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	9300000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6500000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4300000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-10700000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1900000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13100000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	11500000	USD
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8500000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8500000	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	800000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	2000000	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2700000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2700000	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1500000	shares
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	419400000	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	414200000	USD
CY2015Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	30900000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	62700000	USD
CY2016Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	43400000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	88000000	USD
CY2015Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2300000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	4600000	USD
CY2016Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2400000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	4800000	USD
CY2015Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	11700000	USD
CY2016Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	13600000	USD
CY2015Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	401800000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	786900000	USD
CY2016Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	486100000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	972200000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	3705700000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	3663200000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4606100000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4632600000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	426400000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	459100000	USD
CY2015Q4	us-gaap	Line Of Credit LineOfCredit	130000000	USD
CY2016Q2	us-gaap	Line Of Credit LineOfCredit	150000000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3134700000	USD
CY2016Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	3050000000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	36800000	USD
CY2016Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	36500000	USD
CY2015Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2016Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	167900000	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	176700000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	120600000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	45200000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	90000000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	65000000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	125400000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	112800000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3500000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	6400000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3600000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	7500000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42900000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	83800000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	62600000	USD
	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-6800000	USD
	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	2800000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	23400000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	29900000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-99400000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-197700000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-126700000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	204900000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	311900000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	42900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	85400000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	62600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	120600000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17300000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33800000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	18600000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	37300000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	13800000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	27400000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	15000000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	29800000	USD
	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	150400000	USD
CY2015Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2016Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	USD
CY2015Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	0	USD
CY2016Q2	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	0	USD
CY2016Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	72000000	USD
	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties	0	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	126600000	USD
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	168600000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	197000000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	206800000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	200000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	300000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	400000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	600000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	200000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	200000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	300000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	600000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	600000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	100000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	200000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	300000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	800000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	900000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	400000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	600000	USD
CY2015Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	104200000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	207400000	USD
CY2016Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	121500000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	240700000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	328000000	USD
CY2016Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	355500000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	144600000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	154100000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-11000000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6900000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3500000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	700000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1300000	USD
CY2015Q4	us-gaap	Other Notes Payable OtherNotesPayable	39200000	USD
CY2016Q2	us-gaap	Other Notes Payable OtherNotesPayable	43300000	USD
	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	8600000	USD
	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	7600000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	600000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-2000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	24100000	USD
	us-gaap	Payments For Software PaymentsForSoftware	15200000	USD
	us-gaap	Payments For Software PaymentsForSoftware	15200000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	13900000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	37100000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	41900000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	26200000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	33600000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	77700000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9400000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46300000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	71400000	USD
CY2015	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	-71300000	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	-71300000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	700000000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	270000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	165000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5300000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	60200000	USD
	us-gaap	Profit Loss ProfitLoss	119200000	USD
CY2016Q2	us-gaap	Profit Loss ProfitLoss	81200000	USD
	us-gaap	Profit Loss ProfitLoss	157900000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1310100000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1336900000	USD
CY2015Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10900000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	22500000	USD
CY2016Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	15400000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	31900000	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	121100000	USD
CY2016Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	120000000	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	121100000	USD
CY2016Q2	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	120000000	USD
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	546100000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	112800000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	442000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	145000000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	13100000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	611400000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	672700000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	619500000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	764700000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	779300000	USD
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	849400000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-100000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-2700000	USD
CY2015Q2	us-gaap	Supplies Expense SuppliesExpense	31700000	USD
	us-gaap	Supplies Expense SuppliesExpense	63100000	USD
CY2016Q2	us-gaap	Supplies Expense SuppliesExpense	34400000	USD
	us-gaap	Supplies Expense SuppliesExpense	69400000	USD
CY2015Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-300000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-600000	USD
CY2016Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-200000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	-400000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2900000	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	100000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	400000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	100000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	300000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2900000	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2800000	USD
CY2016Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	255300000	USD
CY2016Q2	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	54600000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101300000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99400000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89800000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88400000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	89400000	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and Other Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. On November 25, 2014, the plaintiffs filed another amended complaint to assert new allegations relating to the time period of 1997 to 2002. On December 10, 2014, we filed a motion to dismiss on the grounds the plaintiffs lack standing because their claims are derivative in nature, and the claims are time-barred by the statute of limitations. On May 26, 2016, the court granted our motion to dismiss. The plaintiffs appealed the dismissal of the case to the Supreme Court of Alabama on June 28, 2016. The supreme court has not yet scheduled a hearing on the appeal.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation—</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One of our hospital subsidiaries was named as a defendant in a lawsuit filed August 12, 2013 by an individual in the Circuit Court of Etowah County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Honts</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">v. HealthSouth Rehabilitation Hospital of Gadsden, LLC.</font><font style="font-family:inherit;font-size:10pt;"> The plaintiff alleged that her mother, who died more than three months after being discharged from our hospital, received an unprescribed opiate medication at the hospital. We deny the patient received any such medication, accounted for all the opiates at the hospital and argued the plaintiff established no causal liability between the actions of our staff and her mother’s death. The plaintiff sought recovery for punitive damages. On May 18, 2016, the jury in this case returned a verdict in favor of the plaintiff for </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">. On June 17, 2016, we filed a renewed motion for judgment as a matter of law or, in the alternative, a motion for new trial or, in the further alternative, a motion seeking reduction of the damages awarded (collectively, the “post-judgment motions”). Those post-judgment motions remain pending before the trial court. We intend to vigorously defend ourselves in this case through those motions and by appeal, if necessary. Although we continue to believe in the merit of our defenses and counterarguments, we have recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;"> (including </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> in fees and expenses) in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses and other liabilities</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated balance sheet as of June 30, 2016 with a corresponding receivable of $</font><font style="font-family:inherit;font-size:10pt;">15.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</font><font style="font-family:inherit;font-size:10pt;"> for the portion of the liability we would expect to be covered through our excess insurance coverages, resulting in a net charge of an additional </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other operating expenses</font><font style="font-family:inherit;font-size:10pt;"> in our condensed consolidated statements of operations for the three and six months ended June 30, 2016. The </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> portion of this liability would be a covered claim through our captive insurance subsidiary, HCS, Ltd. As a result of the verdict, we posted a bond in the amount of the judgment pending resolution of our post-judgment motions, and if necessary, any appeals. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Inquiries and Investigations—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the HHS-OIG. The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from the HHS-OIG since December 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. Those subpoenas also requested complete copies of medical records for </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. </font><font style="font-family:inherit;font-size:10pt;">Two</font><font style="font-family:inherit;font-size:10pt;"> of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The most recent subpoenas do not include requests for specific patient files. However, in February 2015, the DOJ requested the voluntary production of the medical records of an additional </font><font style="font-family:inherit;font-size:10pt;">70</font><font style="font-family:inherit;font-size:10pt;"> patients, some of whom were treated in hospitals not subject to the subpoenas, and we provided these records. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule. Under the Medicare rule commonly referred to as the “</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule,” an inpatient rehabilitation hospital must treat </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law, court order, or agreement with the government from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.</font></div></div>

Files In Submission

Name	View Source	Status
0000785161-16-000136-index-headers.html	Edgar Link	pending
0000785161-16-000136-index.html	Edgar Link	pending
0000785161-16-000136.txt	Edgar Link	pending
0000785161-16-000136-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hls-20160630.xml	Edgar Link	completed
hls-20160630.xsd	Edgar Link	pending
hls-20160630_cal.xml	Edgar Link	unprocessable
hls-20160630_def.xml	Edgar Link	unprocessable
hls-20160630_lab.xml	Edgar Link	unprocessable
hls-20160630_pre.xml	Edgar Link	unprocessable
hls10q63016.htm	Edgar Link	pending
hls10q63016ex1011.htm	Edgar Link	pending
hls10q63016ex1012.htm	Edgar Link	pending
hls10q63016ex1013.htm	Edgar Link	pending
hls10q63016ex1014.htm	Edgar Link	pending
hls10q63016ex1015.htm	Edgar Link	pending
hls10q63016ex311.htm	Edgar Link	pending
hls10q63016ex312.htm	Edgar Link	pending
hls10q63016ex321.htm	Edgar Link	pending
hls10q63016ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2016 Q2 Form 10-Q Financial Statement

#000078516116000136 Filed on July 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2016 Q2 Form 10-Q Financial Statement

#000078516116000136 Filed on July 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc